Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-019-05371-0.pdf
Reference75 articles.
1. Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542–e551. https://doi.org/10.1016/s1470-2045(16)30406-5
2. Hansen JD, Du Pasquier L, Lefranc MP, Lopez V, Benmansour A, Boudinot P (2009) The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol 46:457–472. https://doi.org/10.1016/j.molimm.2008.10.007
3. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19:813–824. https://doi.org/10.1093/intimm/dxm057
4. Ma G, Deng Y, Jiang H, Li W, Wu Q, Zhou Q (2018) The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: an updated meta-analysis. Clin Chim Acta 482:101–107. https://doi.org/10.1016/j.cca.2018.03.038
5. Gandini S, Massi D, Mandala M (2016) PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88–98. https://doi.org/10.1016/j.critrevonc.2016.02.001
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping;Pathology - Research and Practice;2024-10
2. Evaluating the Prognostic Role of the PAM50 Signature and Selected Immune-Related Signatures for Recurrence in Patients With T1abN0 Breast Cancer;Clinical Breast Cancer;2024-08
3. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024;Translational Breast Cancer Research;2024-04
4. PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site;International Journal of Clinical Oncology;2024-03-25
5. Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment;Siberian journal of oncology;2024-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3